China IVD market hub

China IVD market

China’s government is investing to build up the country’s in vitro diagnostics (IVD) testing capacity and meet strong clinical demand from an ageing population. With major policies, regulations and the growth of domestic players shaking up the country’s IVD market dynamics, companies are localising and adapting their strategies to stay ahead in this fast-evolving market.

Clearstate offers market data, analysis and forecasts to give you the insight needed to capture opportunities in China, the world’s largest emerging IVD market. Our China IVD market hub is regularly updated to share our findings on this fast-evolving market.

Inquire now

What is China’s IVD market size?

The China IVD market size is estimated at US$17.5bn in 2023. The market is expected to grow at an annual average of 5% in the period of 2023 to 2026.

Understand the China IVD market

Discover more IVD insights and learn how IVD Gateway solutions can help prepare your business for opportunities in China’s IVD market. Examine key themes such as localisation, digitalisation, automation and novel technologies that IVD companies need to address to stay competitive in China.

Explore the latest China in-vitro diagnostics market insights

From market news and trends to analysis, our articles provide concise and up-to-date information about the market potential and adoption trends of IVD innovations across Chinese cities, and where and how fast domestic competition is emerging in key segments of in vitro diagnostics – core labs, molecular diagnostics, point-of-care testing, tissue diagnostics and next-generation sequencing. Explore the latest in policy developments impacting the IVD products and devices market, local competition and prices.

China’s IVD market – sample report

China has been aggressively implementing various policies to control healthcare costs. In recent years, volume-based procurement (VBP) has been one of the most impactful policies, significantly reshaping China’s IVD market landscape.

Disease trends in China

China’s population has reached its peak and is projected to remain above 1.39bn until 2035. After a brief rebound, the number of new-borns is expected to return to its previous downward trend owing to a combination of fewer women of reproductive age and declining fertility rates.

Tissue-based companion diagnostics market to grow for the most common cancers in China

Companion diagnostics (CDx) use is growing as the cancer treatment paradigm-shifts towards immunotherapy and targeted therapy.

Rise of connected blood glucose testing at Chinese hospitals

In China, the use of connected point-of-care (POC) blood glucose testing will play an increasingly important role in diabetes management at hospitals. China has the largest number of diabetes cases in the world.

Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge

The impact of China’s latest covid-19 surge heads the latest quarterly in vitro diagnostics (IVD) market data.

Quarterly Company Insights

Quarterly Company Insights (QCI) provides in-depth reports on China’s top IVD companies’ localised commercial activities in core labs, point-of-care testing, molecular and tissue diagnostics to help you understand the key players’ dynamics in the world’s largest emerging IVD market.

IVD Size & Share

The go-to source for tracking and understanding market size, share and trends in the global in vitro diagnostics market. Granular break-out of data and comprehensive coverage of international and domestic suppliers’ brand share across Asia, Europe, Latin America and the Middle East.

LabPRO Plus

Lab by lab profiles of centralised diagnostics (CEDx) labs, molecular diagnostics labs (MDx) and tissue diagnostics (TDx) labs across hospitals and commercial settings to help your business understand current test, instrument and reagent usage of target customers.

Clearstate newsletter

Sign up to our newsletter for insights into key market data, trends and developments across IVD and Surgical segments from our specialists and analysts.